Assay of AFP in biological fluids and especially serum has traditionally involved radioimmunoassays (RIA) or immunoradiometric techniques (7, 8 We have developed a sensitive noncompetitive "sandwich"-type immunofluorometric assay (ins) for determining AFP in serum and amniotic fluid with use of a novel detection system. A monoclonal "capture" antibody is noncovalently immobilized in a microtiter strip (or plate) well. The detection antibody is a biotinylated affinity-purified antibody, and streptavidin labeled with a new europium chelate, 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA, "Eurofluor STM"; Figure 1) , is used as the fluorescent label. The resulting complex that forms, monoclona.l antibody-AFP-polyclonal antibody-biotinstreptavidin-BCPDA-Eu3, is quantified on the dry surface of the well by excitation with a nitrogen laser beam; the specific delayed fluorescence is monitored at about 615 nm. The sensitivity, precision, and accuracy of the assay are comparable with or better than those of existing techniques. AFP standards. Human AFP (InterMedico, Toronto, Canada) was calibrated against the international reference standard (72/227) for APP. We prepared APP standards in
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Materials and Methods

Reagents
The reaction mixture was then dialyzed twice at 4#{176}C against 5 L ofO.1 mol/L bicarbonate buffer (pH 8.3) containing 0.25 g of sodium azide per liter.
Before use, we diluted the biotinylated antibody solution 300-fold in 10 mmol/L Ti-is HC1 buffer (pH 7.8) containing, per liter, 400 mmnol of KC1, 10 g of bovine serum albumin, 0.1 g of sodium azide, and 0.1 g of thimerosal.
Preparation of labeled streptavidin. After dissolving 5 mg of streptavidin (Sigma) in 33 mL of 0.1 molJL carbonate buffer (pH 9.1), we added to this, with stirring, 7 mg of BCPDA dissolved in 200 L of dimethylformamide, at room temperature.
After 1 h, we dialyzed the reaction mixture three times against 5 L of a 0.1 mol/L solution of NaHCO3 containing 0.25 g of sodium a.zide per liter.
Before use, we diluted the labeled streptavidin solution 50-fold in 50 mmol/L Ti-is HC1 buffer (pH 7.8), containing, per liter, 10 g of bovine serum albumin, 9 g of NaCl, 0.1 g of sodium azide, 0.1 g of thimerosal, and Eu3 to give a final concentration of 10 zmol/L.
Comparison methods. We also used a commercially available radioimmunoassay (Amersham Corp., Arlington Heights, IL 60005) and a time-resolved immunofluorometric procedure (DELFIA hAFP kit; LKB Wallac, Turku, Finland), carrying out both procedures according to the manufacturers' instructions. 
Results
Incubation time and temperature.
We investigated the effect of the incubation time and temperature on the performance of the APP assay. The quality of the calibration curve, the precision of the assay, and the accuracy of measurements were monitored by analyzing a series of 20 clinical samples previously assayed for APP by RIA. We found that a precise and accurate assay could be established if the incubation times were fixed at 45, 45, and 30 miii, respectively, at 37 #{176}C. With this choice, an assay run could be completed in less than 3 h.
Sensitivity and precision. Figure 2 depicts a typical standard curve (log-log plot) . The assay has a dynamic range of 1-1000 ,ug/L (1.03-1030 mt.units/mL) and a detection limit of 0.1 g/L, as calculated from the mean fluorescence + 3 standard deviations of the zero standard. At concentrations of analyte >1 mg/L, the curve is relatively flat and cannot be used for analytical purposes.
Precision studies were performed with 'Fri-level commercial control sera. As shown in Table 1 , the intra-assay coefficients of variation (CVs) for APP concentrations of 21.5, 58, and 170 ng/mL (.ig/L) were 7.6, 5.4, and 6.2%, respectively. Inter-assay CVs for the same controls were 3.9, 8.6, and 1.7%, respectively.
Day-to-day precision, determined over a one-month period for the same controls, was 7.2, 7.3, and 8.7%, respectively.
Recovery and linearity. To assess the recovery of the assay, analyte-supplemented serum samples were prepared as shown in Table 2 . Analytical recovery of APP ranged from 72 to 125% (mean 104 ± 17%).
To evaluate the linearity of the assay, we tested serial dilutions of three different samples and determined the amount of APP in each sample. The concentration of APP decreased linearly with increasing dilution, and the values obtained were those expected, if the value of the undiluted sample is taken as a true value. This finding confhnns that our assay is free of any serum matrix effects. Interference studies. We studied the effect of hemolysis, lipemia, and bilirubin on the performance of the assay, by supplementing serum samples with hemoglobin, triglycerides, and bilirubin. We found no interference from these compounds at concentrations up to 10 g/L (hemoglobin) is carried out after a delay period during which any short-lived fluorescence has ceased. With europium complexes as fluorescent markers, the back-ground fluorescence so observed is essentially only that originating from nonspecific binding of the reagents used.
There are two general approaches to the use of europium complexes in immunoassays. In the first approach, applied successfully by Soini and Hemmula (13-15), europiumlabeled imniunoreactants are used. In the second approach, presented here, chelate-labeled immunoreactants are used. The synthesis and some spectroscopic data of the novel Eu3 chelate 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid are described elsewhere (16). In the present system, fluorescence is quantified directly on the solid support. In the previous system, the final measurement is for Eu3 in solution after its dissociation from the solidphase. The latter approach suffers from vulnerability to Eu3 contamination.
The use of the well-known streptavidin-biotin system in the assay design has a number of advantages: (a) It is a universal detection system in both sandwich and competitive immunoassays. 
In conclusion,
we describe a time-resolved fluorescence immunoassay for APP with use of a novel detection system. The capabilities of the detection system for devising other competitive and non-competitive immunoassays are described elsewhere (17) .
